Document Detail

Angiotensin II receptor blockade with valsartan decreases plasma osteopontin levels in patients with essential hypertension.
MedLine Citation:
PMID:  20664555     Owner:  NLM     Status:  In-Data-Review    
Osteopontin (OPN) has recently emerged as a key factor in both vascular remodelling and development of atherosclerosis. It has been reported that OPN is regulated by the renin-angiotensin-aldosterone system (RAAS). The aim of this study was to clarify the effect of angiotensin II receptor blockade with valsartan on plasma OPN levels in patients with essential hypertension (EHT). Forty-six patients (mean age, 64±11 years) with EHT were randomly assigned to treatment with amlodipine or valsartan. There were no significant differences in baseline clinical characteristics between the two groups. Blood sampling and blood pressure evaluation were performed before and after 24 weeks of treatment. After 24 weeks, both systolic blood pressure (SBP) and diastolic blood pressure (DBP) were decreased significantly and by the same degree in each treatment group. However, valsartan but not amlodipine decreased plasma OPN levels (baseline and 24-week data-valsartan: 614±224 ng ml(-1), 472±268 ng ml(-1), P=0.006; amlodipine: 680±151 ng ml(-1), 687±234 ng ml(-1), P>0.999). A positive correlation between the reduction in OPN and the log natural (ln) C-reactive protein (CRP) was seen in the valsartan-treated group. Stepwise regression analysis showed that treatment with valsartan and the reduction of ln CRP were associated with the reduction in OPN levels, and this association was independent of the reduction in SBP or aldosterone levels (valsartan: β=0.332, P=0.026; ln CRP reduction: β=0.366, P=0.015). These results suggest that suppression of the RAAS and inflammation may decrease plasma OPN levels.
M Kurata; T Okura; J Irita; D Enomoto; T Nagao; M Jotoku; K Miyoshi; V R Desilva; J Higaki
Related Documents :
6996895 - Long-term effects of captopril in hypertension.
2155075 - Failure to visualize bilateral adrenal glands in a patient with primary aldosteronism.
7207565 - Blood pressure in acute and chronic vasopressin excess: studies of malignant hypertensi...
19356005 - Management of primary aldosteronism: its complications and their outcomes after treatment.
3580235 - Evaluation of the combined effects of glycopyrrolate and neostigmine on the lower oesop...
17778355 - Changes in state of stress on the southern san andreas fault resulting from the califor...
Publication Detail:
Type:  Journal Article     Date:  2010-07-22
Journal Detail:
Title:  Journal of human hypertension     Volume:  25     ISSN:  1476-5527     ISO Abbreviation:  J Hum Hypertens     Publication Date:  2011 May 
Date Detail:
Created Date:  2011-04-14     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8811625     Medline TA:  J Hum Hypertens     Country:  England    
Other Details:
Languages:  eng     Pagination:  334-9     Citation Subset:  IM    
1] Department of Integrated Medicine and Informatics, Ehime University Graduate School of Medicine, Shitsukawa, Toon City, Ehime, Japan [2] Division of Pathogenomics, Department of Pathology, Ehime University Graduate School of Medicine, Shitsukawa, Toon City, Ehime, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Association of the leptin gene with knee osteoarthritis susceptibility in a Han Chinese population: ...
Next Document:  Airborne particle exposure and extrinsic skin aging.